# Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 (Which is Planned Use in the Treatment of COVID-19) in Healthy Volunteers

> **NCT04679493** · PHASE1 · COMPLETED · sponsor: **NP Therapeutics** · enrollment: 16 (actual)

## Conditions studied

- Covid19
- Healthy Volunteers

## Interventions

- **DRUG:** XC7 100 mg single
- **DRUG:** XC7 200 mg single
- **DRUG:** Placebo single
- **DRUG:** XC7 200 mg multiple
- **DRUG:** Placebo multiple

## Key facts

- **NCT ID:** NCT04679493
- **Lead sponsor:** NP Therapeutics
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-17
- **Primary completion:** 2021-04-09
- **Final completion:** 2021-04-09
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04679493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04679493, "Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 (Which is Planned Use in the Treatment of COVID-19) in Healthy Volunteers". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04679493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*